Esophageal Cancer Surveillance and Follow-up

Scope and principles

Surveillance should be risk-adapted to the original disease, treatment received, pathological response, recurrence risk, and ongoing symptoms rather than applied as a single schedule to all patients.^{[1]A1c[9]B2b[20]C4} The evidence supplied here supports structured endoscopic follow-up after endoscopic eradication or resection, clinical and nutritional monitoring after esophagectomy, and symptom-triggered imaging for recurrent or metastatic disease.^{[1]A1c[2]A1a[13]A1b[14]B2a[17]B3b[20]C4}

After endoscopic eradication therapy for Barrett’s esophagus

Patients treated with endoscopic eradication therapy (EET) for Barrett’s esophagus (BE) or related neoplasia require surveillance endoscopy because EET reduces, but does not eliminate, the risk of residual or recurrent intestinal metaplasia and neoplasia.^[1]A1c The AGA guideline frames surveillance after EET as a balance between detecting recurrence and limiting procedure-related harms and resource use.^[1]A1c

For practical scheduling, surveillance should begin after documented treatment response and confirmation of complete eradication of visible neoplasia; subsequent intervals should be determined by the highest pretreatment grade of dysplasia or cancer and by findings at follow-up endoscopy.^[1]A1c Patients with high-grade dysplasia or intramucosal neoplasia generally warrant the most intensive early surveillance, followed by lengthening intervals when eradication is sustained.^[1]A1c Any recurrent visible lesion, dysplasia, or persistent BE should prompt expert endoscopic reassessment and management rather than routine continuation of the existing interval.^[1]A1c

The supplied abstract does not report the guideline’s detailed interval table; therefore, local implementation should use the complete AGA recommendations and should document the index pathology, extent of BE, treatment completeness, biopsy findings, and next scheduled examination.^[1]A1c

After endoscopic resection for esophageal squamous cell carcinoma

Surveillance endoscopy is recommended after endoscopic resection of esophageal squamous cell carcinoma (ESCC).^[17]B3b Particular attention is required during the first 24 months, because subsequent advanced ESCC—defined in the cited study as invasion of the muscularis mucosa or deeper—was specifically evaluated when detected within that period after a prior endoscopy.^[17]B3b A negative examination does not exclude later metachronous or recurrent disease; endoscopic inspection should therefore remain systematic and continue beyond the early postoperative period according to lesion burden, resection margins, histology, field cancerization risk, and local protocol.^[17]B3b

Endoscopic submucosal dissection (ESD) and endoscopic radiofrequency ablation (ERFA) have been used for superficial squamous neoplasia, but available comparative evidence is retrospective and does not establish a universal post-treatment surveillance interval.^[18]B3b ESD achieved en-bloc resection in 100.0%, an R0 rate of 90.2%, and a curative-resection rate of 76.1% in the cited cohort; these treatment outcomes support the need to base follow-up intensity on pathology and completeness of resection rather than treatment modality alone.^[18]B3b

After esophagectomy or definitive treatment

Follow-up after curative-intent treatment should include scheduled clinical review for recurrence, treatment toxicity, swallowing dysfunction, nutritional decline, and functional impairment.^{[4]A1b[7]B2a[20]C4} Locoregional recurrence after surgery may occur early; in a salvage-radiotherapy cohort, the median disease-free interval before recurrence was 13.5 months, supporting particularly close clinical assessment during the first 2 years.^[20]C4 Salvage treatment decisions require multidisciplinary review and are not determined by surveillance imaging alone.^[20]C4

Routine follow-up should assess weight, oral intake, dysphagia, reflux, aspiration symptoms, bowel symptoms, fatigue, anxiety, depression, sleep, and activity. A 12-week walking and dietary-education program improved quality-of-life and symptom-related outcomes in a randomized trial with assessments at baseline and 3, 6, and 12 months, supporting incorporation of rehabilitation and dietary review into follow-up visits.^[4]A1b Sarcopenia is associated with adverse perioperative outcomes after esophagectomy, so serial nutritional assessment, muscle-mass or functional assessment when clinically indicated, and early dietetic intervention are appropriate components of surveillance.^[7]B2a

Dumping syndrome is a frequent potential sequela after esophageal cancer surgery, although prevalence estimates vary substantially across studies.^[2]A1a Symptoms should be actively screened for during follow-up rather than elicited only when volunteered; assessment may include postprandial cramping, diarrhea, vasomotor symptoms, palpitations, dizziness, and hypoglycemic symptoms.^{[2]A1a[11]B2b} The cited evidence supports symptom-directed dietary education and treatment, but does not define a single mandatory visit schedule.^{[2]A1a[11]B2b}

Imaging and symptom-triggered assessment

Surveillance imaging should be guided by stage, treatment intent, institutional protocol, and symptoms because the supplied references do not establish one universal imaging timetable.^[9]B2b[20]C4 New dysphagia, progressive weight loss, persistent chest or back pain, cough, hoarseness, bleeding, or focal neurologic symptoms should trigger prompt diagnostic evaluation rather than waiting for the next scheduled visit.^{[14]B2a[20]C4}

Brain metastases from esophageal carcinoma remain relatively uncommon but are clinically serious, and reported incidence has increased in recent years.^[14]B2a Routine brain imaging for asymptomatic patients is not established by the supplied evidence; brain MRI or other neuroimaging should be obtained when neurologic symptoms or signs raise concern.^[14]B2a Primary small-cell carcinoma of the esophagus has a distinct metastatic risk profile, and risk-prediction nomograms have been developed, but their retrospective evidence does not establish a standard surveillance schedule.^[70]

Advanced or metastatic disease

For patients with advanced disease receiving systemic therapy, assessment should follow treatment response, toxicity, and clinical status; pembrolizumab plus chemotherapy has been studied with pembrolizumab administered every 3 weeks for up to 35 cycles in KEYNOTE-590, but treatment-cycle timing is not equivalent to a universal surveillance schedule.^[3]A1b Patients with oligometastatic disease require individualized multidisciplinary surveillance because management may combine systemic therapy, local treatment, both, or best supportive care.^[13]A1b

Operational summary

At every visit, document disease status, symptoms, nutrition, weight, swallowing, functional recovery, psychosocial health, and treatment-related complications.^{[2]A1a[4]A1b[7]B2a[11]B2b} Maintain intensified early follow-up after EET or endoscopic resection, with particular vigilance during the first 24 months after ESCC resection and the first 2 years after curative treatment, while using the complete disease-specific guideline or institutional protocol to assign exact endoscopy and imaging dates.^{[1]A1c[17]B3b[20]C4}

Scope and principles

Recurrence should be assessed as local/intraluminal, locoregional nodal, or distant/metastatic disease, because the available evidence evaluates these patterns using different modalities and clinical contexts. Early recurrence after surgery has been defined as recurrence within 1 year and may be local, distant, nodal, or disseminated; contrast-enhanced CT (CECT) radiomics has been investigated for predicting this outcome in locally advanced esophageal squamous cell carcinoma (ESCC) after trimodal therapy ^[24]A1b. The supplied references do not establish a universal post-treatment surveillance schedule or a validated symptom-triggered versus routine testing strategy.

Endoscopic detection of local recurrence

Upper endoscopy is the principal direct method for evaluating the treated esophageal lumen and anastomosis when local residual or recurrent disease is suspected. In patients with cT1bN0M0 ESCC treated with definitive chemoradiotherapy (DCRT), local residual or recurrent disease occurred despite complete remission, and specific post-treatment endoscopic findings were retrospectively evaluated as markers of non-radical cure ^[32]C4. This supports careful inspection and documentation of the treated lesion, scar, ulceration, mucosal irregularity, and anastomosis, with targeted biopsies of suspicious areas; however, the reference does not provide sufficient data to define a single endoscopic sign as diagnostic.

Artificial intelligence (AI)-assisted real-time esophagogastroduodenoscopy has been evaluated in randomized trials for detection of upper gastrointestinal neoplasms. A 2026 systematic review and meta-analysis pooled neoplasm detection rates and lesions per endoscopy, including subgroup analyses by AI system and pathological type ^[73]. Because the supplied abstract does not report the pooled effect estimates, AI may be considered an adjunct to, rather than a replacement for, expert endoscopic examination during recurrence assessment ^[73]. Screening and early-detection studies of endoscopy, capsule-sponge sampling, and population screening concern previously undiagnosed neoplasia rather than validated detection of post-treatment recurrence and should not be extrapolated as recurrence-surveillance tests ^{[10]B2a[22]C4[74][75]}.

Cross-sectional and functional imaging

CECT remains relevant for evaluating the primary tumor region, lymph nodes, and distant disease, while quantitative CT radiomics has been studied specifically for prediction of recurrence within 1 year after trimodal therapy for locally advanced ESCC ^[24]A1b. Radiomics should therefore be regarded as investigational risk stratification rather than a stand-alone diagnostic test, because the cited study evaluates prediction and does not establish that radiomic features can confirm recurrence ^[24]A1b.

For suspected metastatic disease, 18F-FDG-PET/CT was used to define de-novo oligometastatic disease as ≤5 distant metastases in a multicenter cohort of esophagogastric cancer ^[13]A1b. PET/CT can consequently contribute to whole-body staging when recurrence is suspected, particularly when the number and distribution of lesions may influence consideration of systemic therapy, metastasis-directed therapy, or supportive care; the cohort itself does not establish PET/CT sensitivity or a routine surveillance interval ^[13]A1b.

Diffusion-weighted MRI (DWI) has been studied serially during concurrent chemoradiotherapy for ESCC to predict early treatment response using changes in apparent diffusion coefficient values and RECIST assessment ^[23]C4. This evidence concerns response during active treatment, not the diagnosis of recurrence after treatment completion; DWI should not be substituted for endoscopy, CECT, or PET/CT when recurrence is suspected ^[23]C4.

Confirming and characterizing suspected recurrence

A suspicious endoscopic lesion should be histologically confirmed when feasible before initiating local salvage treatment. The cited literature describes salvage photodynamic therapy for locally recurrent esophageal cancer after definitive chemoradiotherapy, including lesions exceeding the original trial parameters; the initial investigator-initiated trial indications included circumferential involvement of ≤1/2, lesion length of ≤3 cm, and no cervical-esophagus invasion ^[31]C4. These thresholds describe treatment eligibility, not diagnostic criteria, but they emphasize the need to document lesion extent accurately during recurrence assessment ^[31]C4.

Following surgery, salvage radiotherapy or chemoradiotherapy has been retrospectively evaluated for locoregional recurrence, with reported treatment doses of 60 Gy in 20 fractions for radiotherapy alone and 60–70 Gy in 30–35 fractions for concurrent chemoradiotherapy ^[20]C4. Detection should therefore define the recurrence site, disease extent, prior treatment, and disease-free interval before multidisciplinary salvage planning ^[20]C4.

Emerging and non-validated tools

Early tumor shrinkage during immune-checkpoint-inhibitor therapy has been assessed in patients with unresectable or recurrent ESCC, using a 20% decrease at first evaluation as the study cutoff ^[67]B3b. Immune-related adverse events have also been retrospectively examined as correlates of outcomes in unresectable, advanced, or recurrent esophageal cancer treated with immune-checkpoint-inhibitor combinations ^[29]C4. Neither finding is a validated method for detecting recurrence; both relate to treatment response or prognosis after recurrence has already been diagnosed ^{[29]C4[67]B3b}.

Recurrence-free or disease-free survival is an outcome measure and potential surrogate endpoint in esophageal cancer trials, not a clinical detection modality ^[25]B2a. Similarly, recurrence rates reported after endoscopic submucosal dissection, endoscopic submucosal tunnel dissection, or radiofrequency ablation describe post-treatment outcomes for superficial neoplasia and do not provide a general recurrence-detection algorithm ^{[18]B3b[27]B2a}.

Survivorship assessment and follow-up priorities

Survivorship follow-up should extend beyond recurrence surveillance to include nutrition, swallowing, gastrointestinal symptoms, physical function, psychological health, social recovery, and caregiver needs. Patients and families report that persistent symptoms and reduced quality of life are common after oesophago-gastric surgery, while conventional follow-up has often concentrated primarily on recurrence and survival. ^[54]D5 In a patient-perspective survey, respondents identified postoperative symptoms and functional consequences as important determinants of quality of life and expressed preferences regarding the structure and content of follow-up. ^[54]D5

A multidisciplinary survivorship model can incorporate validated patient-reported outcome measures, functional review, anthropometry, and biochemical assessment for micronutrient deficiencies at 6 and 12 months after oesophagectomy. ^[50]D5 An early nutrition and survivorship clinic reported the feasibility of this approach in 75 patients, most of whom had adenocarcinoma and multimodal treatment; the clinic specifically focused on nutritional well-being and recovery after surgery. ^[50]D5 Nutritional-support strategies may be surgical, endoscopic, or radiological, but their comparative effects on patient-reported outcomes remain uncertain because the available evidence is heterogeneous. ^[40]B2a

Nutritional and gastrointestinal sequelae

Dumping symptoms are a clinically important late consequence after oesophageal cancer surgery. In a prospective Swedish cohort assessed 1 year after surgery, both early- and late-onset dumping symptoms were evaluated according to symptom intensity and examined in relation to health-related quality of life, with reassessment at 1.5 years. ^[38]B2b Moderate or severe dumping symptoms were specifically associated with the study’s HRQL outcomes, supporting routine symptom-directed questioning rather than relying only on weight or nutritional laboratory results. ^[38]B2b

Recurrent benign anastomotic or conduit strictures may produce persistent dysphagia and impaired quality of life. Mechanical dilation remains the standard treatment, but refractory strictures may persist despite repeated procedures. ^[44]B2b A prospective, nonrandomized eight-centre trial evaluated a biodegradable stent in patients with refractory benign strictures who had undergone at least 5 dilations or at least 1 radial incision and cutting procedure, had a dysphagia score of 2 or worse, and had an endoscope that could not pass the stricture. ^[44]B2b Such patients require specialist reassessment, including endoscopic evaluation and consideration of advanced therapy when repeated dilation is unsuccessful. ^[44]B2b

Long-term health-related quality of life

Long-term HRQL remains affected after apparently curative oesophagectomy, although outcomes may vary by surgical approach and individual recovery. Disease-free patients assessed more than 2 years after transthoracic or transhiatal oesophagectomy were evaluated with EORTC QLQ-C30 and QLQ-OG25 instruments; the study specifically examined long-term HRQL in distal oesophageal and gastro-oesophageal junction cancer. ^[48]D5 A related comparison of McKeown and Ivor Lewis oesophagectomy evaluated disease-free patients more than 1 year after surgery using the same core and oesophageal modules. ^[49]D5

Postoperative complications may have durable consequences. In the European LASER dataset, disease-free patients assessed more than 1 year after oesophagectomy were compared according to whether complications occurred and according to complication severity, with long-term HRQL as the outcome. ^[53]D5 These findings support documenting major postoperative complications in survivorship records and actively assessing patients with persistent functional or psychological symptoms rather than assuming that resolution of acute morbidity represents full recovery. ^[53]D5

Frailty, rehabilitation, and physical recovery

Frailty and functional reserve should be assessed before and after treatment, particularly in older adults. A feasibility study used the 6-minute walk test, gait speed, hand-grip strength, comorbidity and frailty indices, quality-of-life questionnaires, and CT-based psoas muscle assessment before thoracic surgery for lung or oesophageal cancer. ^[45]C4 In a prospective longitudinal study of 131 older patients undergoing oesophageal cancer surgery, frailty and HRQL were measured preoperatively and at 1 week, 1 month, and 3 months postoperatively to examine their relationship over time. ^[43]B3b

Postoperative rehabilitation may include pulmonary exercises, inspiratory muscle training, coughing techniques, mobility, stretching, and broader multimodal components. A retrospective study of 59 inpatients compared multimodal inpatient rehabilitation with conventional pulmonary rehabilitation after oesophageal cancer surgery and evaluated physical recovery. ^[41]B3b Before or during neoadjuvant therapy, a randomized feasibility trial compared supervised and home-based exercise while providing identical nutritional and psychosocial support; recruitment, retention, and dropout were primary feasibility outcomes. ^[39]C4 A separate randomized trial evaluated a 12-week walking and dietary-education program, with quality of life, anxiety, depression, rest/activity circadian rhythm, and sleep assessed through 12 months. ^[4]A1b

Psychological, caregiver, and social survivorship needs

Psychological distress should be assessed longitudinally. A study of the Managing Cancer and Living Meaningfully intervention reported reductions in psychological distress, anxiety, and depression and improvement in quality of life, with benefit persisting at 1 month after the intervention. ^[51]D5 Informal caregivers of people with upper gastrointestinal cancers experience adjustment challenges and have supportive-care needs that are insufficiently characterized in the qualitative evidence base. ^[37]B2a Follow-up should therefore offer caregiver-inclusive education, signposting, and psychosocial assessment. ^[37]B2a

Employment and social functioning may also be affected during the treatment pathway. A multicentre Japanese cross-sectional study examined job resignation between diagnosis and surgery among employed patients scheduled for curative-intent surgery for gastric or oesophageal cancer and assessed associated HRQL correlates. ^[76] Work status, financial concerns, and return-to-work goals should consequently be included in individualized survivorship assessment. ^[76]

Treatment-related late toxicity beyond surgery

Esophageal brachytherapy has been used as exclusive treatment, as a boost after external-beam radiotherapy, for reirradiation, and for palliation. A retrospective single-centre series of 90 patients treated between 1992 and 2018 described high-dose-rate brachytherapy experience across these indications and reported late follow-up toxicity outcomes. ^[42]C4 Patients previously receiving brachytherapy or reirradiation require individualized assessment for delayed dysphagia, stricturing, ulceration, bleeding, and other local complications, with investigation guided by symptoms and treatment history. ^[42]C4

Practical survivorship checklist

At each clinically appropriate review, assess swallowing and reflux-related symptoms, dumping, weight trajectory, oral intake, enteral-support requirements, micronutrient risk, functional capacity, frailty, respiratory recovery, sleep, anxiety or depression, caregiver strain, and work or financial concerns. ^{[38]B2b[40]B2a[41]B3b[43]B3b[50]D5[51]D5[54]D5[76]} Persistent or progressive dysphagia warrants endoscopic evaluation, and refractory strictures should be discussed with an experienced therapeutic endoscopy team. ^[44]B2b Survivorship care should be multidisciplinary and responsive to patient-reported priorities, because long-term HRQL is influenced by symptoms, complications, treatment approach, physical function, and psychosocial recovery. ^{[48]D5[49]D5[53]D5[54]D5}

The previous section detailed late toxicities. The following addresses patient counselling across follow-up, equipping survivors to recognize early warning signs and adopt practices that mitigate complications and preserve quality of life.

Symptoms to Report at Each Visit

Patients should be explicitly instructed to report any new or worsening symptoms between scheduled visits. The most common and clinically significant include:

• Dumping syndrome - symptoms such as postprandial diaphoresis, palpitations, diarrhea, and early satiety. Dumping syndrome occurs in 78% of patients after esophagectomy at least once during follow-up, with a point prevalence of 40-45% at individual visits ^[11]B2b. Male sex triples the odds (adjusted OR 3.04, 95% CI 1.11-8.17) ^[11]B2b.
• Reflux symptoms - heartburn, regurgitation, and nocturnal cough. Distal or gastroesophageal junction tumors and higher BMI increase early reflux risk, while neoadjuvant therapy, older age, and a longer oral-to-solid diet interval are protective ^[66]B3b. Female patients report greater symptom severity ^[66]B3b.
• Dysphagia or odynophagia - may indicate anastomotic stricture or recurrent disease. After extensive endoscopic submucosal dissection (ESD) involving >75% of the circumference, stricture rates are similar whether oral corticosteroids (66.7%) or intralesional triamcinolone (40%) are used (P = 0.27), but oral corticosteroids require fewer dilation sessions (5 vs. 19, P = 0.04) ^[59]A1b.
• Respiratory symptoms - cough, fever, or purulent sputum. Postoperative pneumonia rates range from 2.0% to 61.5% across studies, with the strongest preoperative predictors being physical frailty (OR 5.17, 95% CI 2.43-11.02), sarcopenia (OR 2.79, 95% CI 1.60-4.86), and low forced expiratory volume (OR 2.73, 95% CI 1.50-4.96) ^[64]B2a.
• Immune-related adverse events (irAEs) - for patients receiving immune checkpoint inhibitors, irAEs occur in 28% of patients; their presence is independently associated with improved progression-free survival (P = 0.003) ^[29]C4. Patients should be counselled to report rash, diarrhea, pneumonitis symptoms, or endocrinopathies promptly.

Lifestyle and Supportive Measures

• Diet and nutrition - small, frequent meals; avoidance of concentrated sweets to reduce dumping symptoms. Both groups in the dumping syndrome cohort experienced postoperative weight loss, with a nonsignificant trend toward greater loss in patients with dumping ^[11]B2b.
• Smoking cessation - smoking is a very strong risk factor for postoperative pneumonia (≥10 significant studies, >50% of all studies) ^[64]B2a. Referral to cessation programs is essential.
• Physical activity - the 30-second chair stand test (CS-30) is more feasible than the 6-minute walk test and significantly improves prediction of postoperative pulmonary complications ^[65]B3b. A perioperative exercise program may reduce risk.
• Weight management - higher BMI increases early reflux risk ^[66]B3b. Overweight patients should receive dietary counselling to mitigate reflux.

Quality of Life Expectations

Longitudinal health-related quality of life (HRQoL) profiles from a nationwide cohort show that 65% of patients have stable-high HRQoL, while 14% deteriorate and 6% fluctuate ^[62]B2b. Female sex and lower BMI are associated with poorer HRQoL ^[62]B2b. Clinicians should set realistic expectations and proactively screen for impairments using validated instruments (e.g., EORTC QLQ-C30, QLQ-OG25).

Screening of Family Members

No evidence in the retrieved literature addresses routine screening of family members for HPV-related cancers in the context of esophageal cancer surveillance. If HPV-associated esophageal squamous cell carcinoma is suspected, clinicians should follow local public health guidelines for HPV-related cancer prevention in at-risk populations.

Pearl: At every follow-up, a structured symptom inquiry for dumping, reflux, dysphagia, and respiratory symptoms, combined with proactive lifestyle counselling on diet, smoking cessation, and exercise, can identify complications early and improve long-term quality of life in esophageal cancer survivors.

Part of the Esophageal Cancer family. Cross-cutting management is split across dedicated child pages:

• Esophageal Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Esophageal Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
• Esophageal Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
• Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
• Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.